MedPath

Regor's Obesity Pill Shows Modest Weight Loss in Phase 2a, Advances to New Trial

Regor's obesity treatment has demonstrated modest weight loss results in its Phase 2a trial and is now moving forward into a new clinical trial.

Regor's innovative obesity pill has recently completed its Phase 2a trial, revealing modest weight loss outcomes among participants. Despite the muted results, the development team is optimistic about the potential of their treatment and has announced the commencement of a new trial to further evaluate its efficacy and safety. This next phase of research aims to build upon the initial findings, with the hope of offering a new, effective option for individuals struggling with obesity. The progression into a new trial underscores the commitment of Regor's team to advancing obesity treatment options and addressing the complex challenges associated with weight management.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Eli Lilly's Omvoh (mirikizumab) for Crohn's Disease and Roche's Susvimo Implant for Diabetic Macular Edema

Eli Lilly's Omvoh (mirikizumab) has received FDA approval for treating moderate to severe Crohn's disease in adults, marking a new option targeting the IL-23 pathway.
Roche's Susvimo implant has been re-approved by the FDA for diabetic macular edema (DME), offering a long-term treatment alternative with reduced injection frequency.

Regor's Oral GLP-1RA RGT-075 Shows Promise in Phase 2a Obesity Trial

Regor Therapeutics' RGT-075, an oral GLP-1 receptor agonist, demonstrated a statistically significant 5% placebo-adjusted weight loss in obese patients.
The Phase 2a trial showed a favorable safety profile for RGT-075, with adverse event-related discontinuation rates similar to placebo.

AbbVie Writes Off $3.5B on Cerevel Drug After Phase 2 Failures

AbbVie has decided to write off $3.5 billion invested in a Cerevel drug following unsuccessful Phase 2 clinical trials.

Advancements in Clinical Trials: Cell Therapies for Parkinson's, Protein Degraders for IgAN, High-Dose Wegovy, Schizophrenia Treatment, and Stem Cell Therapy for IVF

BlueRock Therapeutics, a Bayer subsidiary, is advancing its cell therapy for Parkinson's disease directly to a Phase 3 trial, aiming to provide a novel treatment option.
Biohaven is moving its protein degrader for IgA nephropathy (IgAN) into Phase 3 trials after promising early results, addressing a significant unmet need in kidney disease.

Metsera's MET-097i Demonstrates Significant Weight Loss in Phase 2a Trial, Supporting Monthly Dosing Potential

Metsera's MET-097i, an ultra-long acting GLP-1 receptor agonist, showed substantial placebo-adjusted weight loss of up to 11.3% after 12 weeks in a Phase 2a trial.
The study indicated a dose-dependent weight reduction with individual responses reaching ~20% in the 1.2mg dose cohort, and no weight loss plateau was observed.

Acelyrin's Stock Drops Due to Mixed Phase 2 Data

Acelyrin reports mixed results from Phase 2 trials of a potential treatment for thyroid eye disease, leading to a drop in stock prices.

Bristol Myers' TYK2 Inhibitor Shows Promise in Phase 3 Psoriatic Arthritis Trials

Bristol Myers Squibb's TYK2 inhibitor has demonstrated success in a pair of Phase 3 clinical trials targeting psoriatic arthritis, marking a significant advancement in the treatment of this condition.

Gan & Lee's Oral GLP-1 Agonist GZR18 Shows Promise in Phase 1 Trial

Gan & Lee Pharmaceuticals announced positive Phase 1 results for its oral GLP-1 receptor agonist (RA) GZR18 tablets in healthy participants.
Participants treated with GZR18 experienced an average weight reduction of 4.16% after two weeks, with continued loss after discontinuation.

Sanofi Highlights Phase 3 Sarclisa Data in Multiple Myeloma Treatment

Sanofi has recently showcased promising Phase 3 data for its Sarclisa treatment in multiple myeloma, aiming to compete with J&J's Darzalex.

Structure's Obesity Pill Shows Promising Weight Loss Results in Study

Structure Therapeutics' experimental GLP-1 pill, GSBR-1290, demonstrated significant weight loss in obese or overweight individuals over a three-month period, outperforming a placebo. The Phase 2a study results showed an average body weight reduction of 6.2% compared to placebo, with one-third of participants losing 10% or more of their body weight. The company is advancing to a Phase 2b study to test additional doses.

Reference News

[1]
Regor's obesity pill posts muted weight loss in Phase 2a, enters new trial - Endpoints News
endpts.com · Jan 13, 2025

Endpoints subscribers can request a magic link for password-free login, valid once for 24 hours. Alternatively, a passwo...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy